TOP > 外国特許検索 > METHOD FOR ASSESSING POSSIBILITY OF ONSET OR PROGRESSION OF CHRONIC KIDNEY GRAFT REJECTION AND CHRONIC KIDNEY DISEASE, TEST KIT, AND PHARMACEUTICAL COMPOSITION

METHOD FOR ASSESSING POSSIBILITY OF ONSET OR PROGRESSION OF CHRONIC KIDNEY GRAFT REJECTION AND CHRONIC KIDNEY DISEASE, TEST KIT, AND PHARMACEUTICAL COMPOSITION NEW

外国特許コード F210010569
整理番号 (S2020-0155-N0)
掲載日 2021年11月1日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2021JP003576
国際公開番号 WO 2021153798
国際出願日 令和3年2月1日(2021.2.1)
国際公開日 令和3年8月5日(2021.8.5)
優先権データ
  • 特願2020-015303 (2020.1.31) JP
発明の名称 (英語) METHOD FOR ASSESSING POSSIBILITY OF ONSET OR PROGRESSION OF CHRONIC KIDNEY GRAFT REJECTION AND CHRONIC KIDNEY DISEASE, TEST KIT, AND PHARMACEUTICAL COMPOSITION NEW
発明の概要(英語) The present invention provides a method for assessing the possibility of onset or progression of chronic kidney graft rejection and chronic kidney disease in a subject, by using, as an indicator, the mass of the SYT17 protein in a urine sample collected from the subject. The present invention also provides: a pharmaceutical composition that is for prophylaxis and/or treatment of chronic kidney graft rejection or chronic kidney disease and that contains at least one substance selected from the group consisting of specific antibodies for SYT17 and derivatives thereof, and inhibitory nucleic acids against SYT17; and a test kit that is for assessing the possibility of onset or progression of chronic kidney graft rejection and chronic kidney disease and that contains a specific antibody for SYT17 or a derivative thereof.
従来技術、競合技術の概要(英語) BACKGROUND ART
Chronic kidney disease (Chronic Kidney Diseases, CKD) refers to a state in which nephropathy typified by proteinuria and/or renal decline using glomerular filtration rate as an index persist for three months or longer, and one person affects eight adults in Japan. When symptoms of chronic kidney disease have progressed leading to end-stage renal failure, the efficacy of drug therapy is not expected and many patients are forced to artificial dialysis. Because artificial dialysis is symptomatic, patients suffering from end-stage renal failure need to continue to undergo artificial dialysis for a long time, and the physical and economic burden on them is great. Further, increased dialysis costs have become a concern over medical economy.
In the diagnosis of chronic kidney disease, renal function has been evaluated by biomarkers such as urine protein, urine albumin, serum creatinine (Cre), urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). Although these biomarkers have the advantage of being conveniently measurable or calculable, they are not suitable for early and sensitive detection of renal dysfunction progression.
Also, the only radical therapy for end-stage renal failure is renal transplantation. The data in the United States Kidney Data System (Non-Patent Document 1) in 2013 shows that the viability of those receiving renal transplantation is better than dialyzed patients.
A major problem affecting the success rate of renal transplantation is immune rejection to allograft. Recent developments in immunosuppressive agents and medical techniques have significantly reduced the risk of acute immune rejection. However, relatively slowly progressing chronic rejection, represented by chronic active antibody-related rejections (Chronic active antibody-mediated rejection, CAAMR), remains difficult to overcome.
Chronic rejection is a rejection that occurs 3 months or less after renal transplantation. Chronic rejection often progresses gradually while no clear clinical symptoms are observed, and failure to take appropriate action is likely to lead to loss of transplant renal function. Diagnosis of chronic rejection is generally performed by biological tissue diagnosis (biopsy) of grafts. Biopsies, however, are burdensome on subjects and are not a simple method. Biopsies may also underestimate the grade of rejection or miss the lesion. Therefore, a method for conveniently and accurately determining the likelihood of onset or progression of chronic rejection is beneficial for diagnosing chronic rejection, determining the appropriate timing of performing biopsies, and performing prophylactic or therapeutic treatment for chronic kidney disease at the appropriate timing, and has important significance in renal transplant therapy.
On the other hand, the protein family called synaptotagmin (synaptotagmins) is known. Synaptotagmin is a membrane protein present on synaptic vesicles identified as calcium-phospholipid binding molecules and is believed to function as a calcium sensor in exocytosis (exocytosis) from synaptic vesicles due to their ability to bind calcium ions.
The synaptotagmin family reports the presence of 17 isoforms in humans, most of which have two transmembrane and cytoplasmic regions on the N and C C2 regions on the cytoplasmic region. The protein called synaptotagmin-17 (Synaptotagmin-17, SYT17) has two RNA-like domains structurally homologous to the C-terminal C2 region common to the human synaptotagmin family, but does not have a transmembrane region at the N-terminal.
It has been reported that SYT17 protein is expressed in brain and kidneys, and particularly increases in hippocampus in kainate-induced rat epileptic seizure models and in proximal tubules in kidneys after ischemic reperfusion injury, and that the expression level changes depending on the pathology (NpL 2 and NpL 3). However, no reports have been found previously regarding variations in the functional role and expression of SYT17 protein in chronic kidney disease and chronic rejection.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • MURAKAMI Masaaki
  • KAMIMURA Daisuke
  • TAKADA Yusuke
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS IT JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close